全球新生儿筛检市场

全球新生儿筛检市场预计到2030年将达到19亿美元。

2024年全球新生儿筛检市场规模估计为13亿美元，预计2030年将达到19亿美元，在分析期间（2024-2030年）内复合年增长率（CAGR）为7.2%。本报告分析的细分市场之一－新生儿筛检耗材，预计复合年增长率为7.5%，到分析期末将达到14亿美元。新生儿筛检设备细分市场预计在分析期间内复合年增长率为6.3%。

美国市场规模估计为3.306亿美元，而中国市场预计将以10.6%的复合年增长率成长。

据估计，2024年美国新生儿筛检市场规模将达3.306亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到4.672亿美元，在2024年至2030年的分析期内，复合年增长率（CAGR）将达到10.6%。其他值得关注的区域市场分析包括日本和加拿大，预计在分析期间内，两国的复合年增长率分别为3.6%和6.4%。在欧洲，德国的复合年增长率预计约为4.2%。

全球新生儿筛检市场—主要市场趋势与驱动因素概述

什么是新生儿筛检？为什么它很重要？

新生儿筛检是一项重要的公共卫生项目，旨在对新生儿进行出生后立即筛检，以发现某些遗传、代谢和发育障碍。这些筛检对于及早发现疾病至关重要，因为这些疾病若不及时治疗，可能导致严重的健康问题，包括发育迟缓、身体残疾甚至死亡。透过新生儿筛检早期发现疾病，可以采取适当的干预措施，例如药物治疗、饮食调整和手术，从而预防长期併发症，提高儿童的生活品质。

新生儿筛检计画通常包括多种疾病的检测，例如甲状腺机能低下症（PKU）、先天性甲状腺功能低下症、镰状细胞疾病和囊肿纤维化。技术的不断进步正在扩大可检测疾病的范围，使新生儿筛检成为现代医学中不可或缺的工具。透过早期发现这些疾病，新生儿筛检计画有助于降低婴儿死亡率，并改善整体公共卫生状况。

新生儿筛检市场正在如何发展？

新生儿筛检市场正受益于技术进步和筛检项目范围的不断扩大而迅速发展。其中，串联式质谱质谱（MS/MS）技术的日益普及是推动市场发展的关键趋势之一。这项技术透过对单份血液样本进行检测，即可检测多种代谢性疾病，从而实现更快、更准确、更全面的检测，彻底革新了新生儿筛检。此外，包括次世代定序（NGS）在内的基因筛检技术也正被整合到新生儿筛检计画中，从而能够检测出更广泛的遗传性疾病，包括罕见疾病。

另一个重要趋势是新生儿筛检中就地检验（POC​​T）的普及。 POCT设备便携，可在床边即时检测并获得结果，从而缩短确诊疾病的治疗启动时间。数位健康平台的扩展也推动了市场发展，简化了数据收集、分析和报告流程，提高了新生儿筛检的效率。这种发展使得更多婴儿能够更快筛检，尤其是在医疗基础设施匮乏的地区。

哪些疾病正在推动新生儿筛检的需求？

多种疾病推动了新生儿筛检的需求，其中苯酮尿症 (PKU) 和先天性甲状腺机能低下症代谢性疾病是最常见的筛检项目。如果这些疾病未能早期发现，可能导致严重的发育障碍，但透过适当的干预，其影响可以显着降低。囊肿纤维化和镰状细胞疾病等遗传性疾病也是推动筛检需求的主要因素，因为早期治疗可以预防严重的併发症，并改善长期健康。

此外，溶小体储积症（LSDs）是一组罕见的遗传性疾病，正日益纳入新生儿筛检计画。诊断技术的进步使得更多罕见疾病得以检测，早期治疗可以改善患儿的预后。需要早期饮食干预的遗传性代谢紊乱病例的增加，也促使全球对新生儿筛检计画的需求不断增长。

新生儿筛检市场的主要成长要素是什么？

新生儿筛检市场的成长受多种因素驱动，其中包括遗传性和代谢性疾病盛行率的不断上升，这些疾病需要早期诊断和介入。政府旨在扩大新生儿筛检计画的强制规定和政策是关键驱动因素，确保了常规检测涵盖的疾病种类不断增加。技术进步，特别是质谱和基因定序技术的进步，也透过实现更全面、更准确的筛检，推动了市场成长。

另一个重要因素是医护人员和家长日益认识到早期检测对于预防长期健康併发症的重要性。医疗基础设施的改善，尤其是在发展中地区，正在扩大新生儿筛检的覆盖范围，从而促进市场成长。此外，公共卫生机构与私人公司之间合作的加强，也有助于先进筛检技术的应用，进而改善患者的治疗效果。

部分：

产品类型（耗材、设备）、检测类型（干血斑检测、听力筛检检测、严重心臟疾病（CCHD）筛检检测）、技术（免疫检测/酵素检测法、串联式质谱质谱法、检测法、听力筛检技术、脉搏血氧计、其他技术）

受访公司范例

• AB Sciex LLC
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare
• Masimo Corporation
• Medtronic PLC
• Natus Medical, Inc.
• PerkinElmer, Inc.
• Trivitron Healthcare
• Waters Corporation

人工智慧集成

我们正在利用检验的专家内容和人工智慧工具，改变您分析市场和竞争情报的方式。

Market Glass, Inc. 并没有采用典型的 LLM 或产业专用的SLM 方法，而是建立了一个由世界各地领域专家精心策划的内容库，其中包括影片转录、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

在最新发布的报告中，Market Glass, Inc. 将关税对地理市场的影响纳入考量，并根据公司总部所在地、製造地以及进出口（成品和OEM产品）情况，预测企业竞争地位的变化。这种复杂多变的市场现实将对竞争对手产生许多影响，包括销货成本增加、盈利下降以及供应链重组。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章 市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲
• 亚太地区
• 澳洲
• 印度
• 韩国
• 亚太其他地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Newborn Screening Market to Reach US$1.9 Billion by 2030

The global market for Newborn Screening estimated at US$1.3 Billion in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Newborn Screening Consumables, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Newborn Screening Instruments segment is estimated at 6.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$330.6 Million While China is Forecast to Grow at 10.6% CAGR

The Newborn Screening market in the U.S. is estimated at US$330.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$467.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Newborn Screening Market - Key Trends & Drivers Summarized

What Is Newborn Screening and Why Is It Essential?

Newborn screening is a vital public health program that tests infants for certain genetic, metabolic, and developmental disorders shortly after birth. These screenings are essential for detecting conditions that, if left untreated, can lead to severe health problems, including developmental delays, physical disabilities, and even death. Early detection through newborn screening allows for timely interventions, such as medications, dietary changes, or surgeries, which can prevent long-term complications and improve the child’s quality of life.

Newborn screening programs typically include tests for a variety of conditions, such as phenylketonuria (PKU), congenital hypothyroidism, sickle cell disease, cystic fibrosis, and more. With the continuous advancement in technology, the range of detectable disorders is expanding, making newborn screening an indispensable tool in modern healthcare. By identifying these conditions early, newborn screening programs contribute to reducing infant mortality and improving overall public health outcomes.

How Is the Newborn Screening Market Evolving?

The newborn screening market is evolving rapidly, driven by technological advancements and the expansion of screening panels. One of the key trends shaping the market is the increasing use of tandem mass spectrometry (MS/MS), a technology that allows for the detection of multiple metabolic disorders from a single blood sample. This technology has revolutionized newborn screening by enabling faster, more accurate, and comprehensive testing. Additionally, genetic screening techniques, including next-generation sequencing (NGS), are being integrated into newborn screening programs, allowing for the detection of a broader range of genetic conditions, including rare diseases.

Another significant trend is the shift towards point-of-care testing (POCT) for newborn screening. POCT devices are portable and enable immediate testing and results at the bedside, reducing the time it takes to begin treatment for diagnosed conditions. The expansion of digital healthcare platforms is also playing a role in the evolution of the market by streamlining data collection, analysis, and reporting processes, leading to more efficient newborn screening workflows. This evolution is allowing more infants to be screened faster, particularly in regions where access to healthcare infrastructure may be limited.

Which Conditions Are Driving the Demand for Newborn Screening?

Several conditions are driving the demand for newborn screening, with metabolic disorders such as phenylketonuria (PKU) and congenital hypothyroidism being among the most commonly screened. These conditions can cause serious developmental issues if not detected early, but with appropriate interventions, their impacts can be significantly mitigated. Genetic disorders, such as cystic fibrosis and sickle cell disease, are also major drivers of screening demand, as early treatment can prevent severe complications and improve long-term health outcomes.

Additionally, lysosomal storage disorders (LSDs), which are a group of rare genetic conditions, are increasingly being included in newborn screening panels. As diagnostic technologies improve, more rare diseases are being detected, leading to early treatments that can improve the prognosis for affected children. The rise of inherited metabolic disorders, which require early dietary interventions, is also contributing to the growing demand for newborn screening programs across the globe.

What Are the Key Growth Drivers in the Newborn Screening Market?

The growth in the newborn screening market is driven by several factors, including the increasing prevalence of genetic and metabolic disorders, which necessitate early diagnosis and intervention. Government mandates and initiatives focused on expanding newborn screening programs are a key driver, as they ensure that a growing number of conditions are included in routine testing. Technological advancements, particularly in mass spectrometry and genetic sequencing, are also propelling market growth by enabling more comprehensive and accurate screening.

Another important factor is the rising awareness among healthcare providers and parents about the importance of early detection in preventing long-term health complications. As healthcare infrastructure improves, especially in developing regions, access to newborn screening is expanding, contributing to market growth. Additionally, collaborations between public health organizations and private companies are increasing, leading to more widespread adoption of advanced screening technologies and better patient outcomes.

SCOPE OF STUDY:

The report analyzes the Newborn Screening market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Consumables, Instruments); Test Type (Dry Blood Spot Tests, Hearing Screening Tests, Critical Congenital Heart Disease (CCHD) Screening Tests); Technology (Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry, Other Technologies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

• AB Sciex LLC
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare
• Masimo Corporation
• Medtronic PLC
• Natus Medical, Inc.
• PerkinElmer, Inc.
• Trivitron Healthcare
• Waters Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Global Economic Update
  • Newborn Screening - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Awareness of Early Detection and Prevention Drives Growth in Newborn Screening Programs Globally
  • Increasing Adoption of Genetic and Metabolic Screening Expands Opportunities for Early Diagnosis of Congenital Disorders
  • Technological Advancements in Mass Spectrometry Propel Growth in Newborn Screening for Rare Metabolic Disorders
  • Growing Focus on Early Detection of Cystic Fibrosis and Sickle Cell Disease Strengthens Demand for Newborn Screening
  • Expansion of Government-Funded Newborn Screening Programs Drives Adoption in Public Health Systems Worldwide
  • Increasing Use of Tandem Mass Spectrometry (MS/MS) in Newborn Screening Expands Precision Diagnosis Capabilities
  • Rising Adoption of DNA-Based Screening Technologies for Inherited Disorders Strengthens Market for Genomic Newborn Testing
  • Growing Demand for Point-of-Care Newborn Screening Expands Access to Early Detection in Remote and Low-Income Regions
  • Emerging Focus on Screening for Lysosomal Storage Disorders Propels Innovation in Newborn Screening Assays
  • Increasing Use of Digital Data Management Systems in Newborn Screening Programs Drives Demand for Integrated Solutions
  • Rising Demand for Expanded Newborn Screening for Immunodeficiencies and Endocrine Disorders Expands Addressable Market
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Newborn Screening Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Newborn Screening by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dry Blood Spot Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Dry Blood Spot Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hearing Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hearing Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Critical Congenital Heart Disease (CCHD) Screening Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Immunoassays & Enzymatic Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Immunoassays & Enzymatic Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Tandem Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Tandem Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Molecular Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Molecular Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hearing Screening Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hearing Screening Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pulse Oximetry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pulse Oximetry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• JAPAN
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• CHINA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• EUROPE
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Newborn Screening by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• FRANCE
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• GERMANY
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Newborn Screening by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• INDIA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Newborn Screening by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Newborn Screening by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Newborn Screening by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030
• AFRICA
  • Newborn Screening Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Newborn Screening by Product Type - Consumables and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Newborn Screening by Product Type - Consumables and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Newborn Screening by Product Type - Percentage Breakdown of Value Sales for Consumables and Instruments for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Newborn Screening by Test Type - Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Newborn Screening by Test Type - Percentage Breakdown of Value Sales for Dry Blood Spot Tests, Hearing Screening Tests and Critical Congenital Heart Disease (CCHD) Screening Tests for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Newborn Screening by Technology - Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Newborn Screening by Technology - Percentage Breakdown of Value Sales for Immunoassays & Enzymatic Assays, Tandem Mass Spectrometry, Molecular Assays, Hearing Screening Technologies, Pulse Oximetry and Other Technologies for the Years 2015, 2025 & 2030

IV. COMPETITION